Why Aileron Shares Are Falling Today

Aileron Therapeutics (NASDAQ:ALRN) announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated non-small cell lung cancer (NSCLC) undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors.
ALRN-6924-treated patients could stay on chemotherapy treatment longer, completing 93% of the first four cycles of carboplatin/pemetrexed administered compared to 78% on placebo.
This imbalance of completed cycles may have introduced a bias against ALRN-6924 on the composite primary endpoint.
The imbalance increases further when looking at percentages of patients completing six cycles of treatment (79% on ALRN-6924 versus 57% on placebo).
This is reflected in the progression-free survival, which was 4.6 months in the ALRN-6924 arm versus 3.2 months in the placebo arm.
ALRN-6924-treated patients demonstrated 56% of cycles free from serious/severe hematologic toxicities and related events compared to 50% on placebo.
Aileron plans to stop further enrollment in the NSCLC trial and apply key learnings to strengthen the Phase 1b breast cancer trial.
Additionally, Aileron plans to modify the dosing strategy for the trial and will not further enroll additional patients in the ongoing 0.3 mg/kg and 0.6 mg/kg dose cohorts.
Price Action: ALRN shares are down 33.60% at $0.27 during the premarket session on the last check Wednesday.

To add Benzinga News as your preferred source on Google, click here.

Benzinga